TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2296878
Drug: Nifedipine, 10
Normalized name: Nifedipine, 10 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine, 10 mg three times daily
Study: 25464907
Drug: UMEC 15.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: UMEC 15.6 mcg once daily (OD)
Study: 25464907
Drug: UMEC 125
Normalized name: Umecta
Approvals — FDA: no, EMA: no, PMDA: no
Description: UMEC 125 mcg once daily (OD)
Study: 25464907
Drug: UMEC (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: UMEC (various doses)
Study: 23305962
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (in concurrent study)
Study: 21353673
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg letrozole daily for 7 days
Study: 19152549
Drug: Nabumetone 1
Normalized name: nabumetone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabumetone 1 g
Study: 17415139
Drug: Pulse therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse therapy (300 mg dexamethasone for 3 consecutive days followed by 4 days of placebo)
Study: 17415139
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (prednisone 70 mg per day tapered in steps of 10 mg per day to 0 mg)
Study: 16506546
Drug: DEC +
Normalized name: Zodryl DEC
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEC + Ivermectin 200mcg (6mg/kg body weight + 200 mcg/kg body weight)
Study: 16506546
Drug: DEC +
Normalized name: Zodryl DEC
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEC + Ivermectin 400mcg (6mg/kg body weight + 400 mcg/kg body weight)
Study: 17671254
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone (200 mg each night) from 24 to 34 weeks of gestation
Study: 17671254
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone (200 mg each night)
Study: 8723580
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa (300 or 600 IU/kg) administered three times (days 1, 4, and 7)
Study: 6125676
Drug: Amoxycillin 500
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin 500 mg and clavulanic acid 125 mg
Study: 6125676
Drug: Amoxycillin 500
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin 500 mg and clavulanic acid 250 mg
Study: 6125676
Drug: Amoxycillin 500
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin 500 mg
Study: 25247908
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25% + 1 μg/kg dexmedetomidine (Group BD)
Study: 20605648
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBO) - 100% oxygen at 2.4 atmospheres absolute for 100 min on 30 occasions over 6 weeks.
Study: 16075824
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment in Northern Americas (NA)
Study: 16075824
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment in Caribbean (CA)
Study: 16075824
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment in Eurasia (EA)
Study: 12436031
Drug: Prophylactic barbiturate
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic barbiturate therapy
Study: 12436031
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate and calcium channel blockers
Study: 2106545
Drug: Daily infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily infusions of 200 cc of a 20% lipid emulsion with TPN for the first week, followed by daily intravenous lipid for the next 3 weeks (0.7 g lipid/kg BW/day and approximately 280 mg of choline/day)
Study: 2106545
Drug: TPN without
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPN without lipid for the first week, followed by daily intravenous lipid for the next 3 weeks
Study: 31471494
Drug: Subcutaneous needle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous needle drainage
Study: 27143873
Drug: Lysozyme (270
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysozyme (270 mg) administered orally for 52 weeks as an add-on to standard therapies
Study: 27143873
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered orally for 52 weeks as an add-on to standard therapies
Study: 19963442
Drug: Insulin-resistant subjects
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-resistant subjects with impaired fasting glycaemia (IFG)
Study: 19963442
Drug: Insulin-resistant subjects
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-resistant subjects with normal glucose regulation (NGR)
Study: 15721501
Drug: Egg ingestion
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Egg ingestion (2 eggs daily for 6 weeks)
Study: 15721501
Drug: Oat ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oat ingestion (oats daily for 6 weeks)
Study: 7611203
Drug: Bismuth subsalicylate
Normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bismuth subsalicylate (524 mg q.i.d.) and metronidazole (250 mg q.i.d. for the first 2 weeks) for 4 weeks
Study: 628361
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g probenecid
Study: 628361
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day benzbromaron
Study: 628361
Drug: 300 mg/day
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/day benzbromaron
Study: 628361
Drug: 2 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g/day probenecid
Study: 30635187
Drug: Trifecta biological
Normalized name: Trifena
DrugBank: (+)-menthol (DB11344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trifecta biological valve
Study: 30635187
Drug: Mosaic Ultra
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosaic Ultra biological valve
Study: 18445058
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (N/S) infusion at a rate of 800 ml/hour during DSE
Study: 15943850
Drug: famotidine 20
Normalized name: famotidine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: famotidine 20 mg bd
Study: 7564481
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of oral methotrexate weekly
Study: 7006657
Drug: dezocine 5
Normalized name: dezocine 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: dezocine 5 mg
Study: 7006657
Drug: dezocine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: dezocine (all doses)
Study: 25622538
Drug: Guanidinoacetic acid
Normalized name: Guanidinoacetic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanidinoacetic acid (GAA) 1.2 g
Study: 25622538
Drug: Guanidinoacetic acid
Normalized name: Guanidinoacetic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanidinoacetic acid (GAA) 2.4 g
Study: 25622538
Drug: Guanidinoacetic acid
Normalized name: Guanidinoacetic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanidinoacetic acid (GAA) 4.8 g
Study: 18838053
Drug: Teriparatide 20
Normalized name: TERIPARATIDE 200UNT/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide 20 µg/day for one year
Study: 16026869
Drug: Clopidogrel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (75 mg/day, 300 mg loading dose within 24 h prior to hospital admission) plus standard therapy (including ASA, 75‐325 mg/day) for 1 year
Study: 16026869
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy alone (including ASA, 75‐325 mg/day) for life
Study: 15556258
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (600 IU=540 mg vitamin E emulsion)
Study: 2894219
Drug: Nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 10 and 20 mg
Study: 25100106
Drug: Subcutaneous progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous progesterone (Prolutex) 25 mg daily
Study: 25100106
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone (Endometrin) 100 mg bid daily
Study: 25100106
Drug: Subcutaneous progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous progesterone (Prolutex)
Study: 22497752
Drug: Aclidinium 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aclidinium 100 μg
Study: 18281658
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg orally daily until progression
Study: 18281658
Drug: Carboplatin (AUC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (AUC 6) and paclitaxel (200 mg/m² day 1 every 3 weeks) for up to four cycles
Study: 10942632
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment (9.5 microg/kg/day) for 9 months
Study: 8630191
Drug: Intensive outpatient
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive outpatient therapy (1 hr each of physical and occupational therapy, four times per week, for 12 weeks)
Study: 8630191
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment supplied)
Study: 8400928
Drug: levodopa/dopa decarboxylase
Approvals — FDA: no, EMA: no, PMDA: no
Description: levodopa/dopa decarboxylase inhibitor alone (arm 1)
Study: 8400928
Drug: levodopa/decarboxylase inhibitor/selegiline
Approvals — FDA: no, EMA: no, PMDA: no
Description: levodopa/decarboxylase inhibitor/selegiline in combination (arm 2)
Study: 3553802
Drug: Killed, armadillo-derived
Approvals — FDA: no, EMA: no, PMDA: no
Description: Killed, armadillo-derived M. leprae vaccine (1.5 x 10^7 bacilli)
Study: 3553802
Drug: Killed, armadillo-derived
Approvals — FDA: no, EMA: no, PMDA: no
Description: Killed, armadillo-derived M. leprae vaccine (5 x 10^7 bacilli)
Study: 3553802
Drug: Killed, armadillo-derived
Approvals — FDA: no, EMA: no, PMDA: no
Description: Killed, armadillo-derived M. leprae vaccine (1.5 x 10^8 bacilli)
Study: 3553802
Drug: Killed, armadillo-derived
Approvals — FDA: no, EMA: no, PMDA: no
Description: Killed, armadillo-derived M. leprae vaccine (5 x 10^8 bacilli)
Study: 21391924
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) - 100 mg/kg bolus IV over 15 min, followed by 40 mg/kg/day IV infusion for 24 h
Study: 19364873
Drug: Sulfadoxine-pyrimethamine (SP)
Normalized name: pyrimethamine / sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine-pyrimethamine (SP) single-dose treatment
Study: 15084901
Drug: Nefazodone (200-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone (200-600 mg/day)
Study: 9771299
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml kg‐1 of crystalloid fluid preload over 20 min
Study: 7830390
Drug: Carbohydrate maltodextrin
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate maltodextrin supplement (MD; 5% maltodextrin + 2% fructose) at dosage of 0.25 g.kg‐1 body weight (mean intake rate, total: 37 g.h‐1, 148 g)
Study: 7830390
Drug: Carbohydrate maltodextrin
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate maltodextrin supplement (MD)
Study: 3034318
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg once daily
Study: 3071596
Drug: Captopril 100
Normalized name: captopril 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 100 mg once daily
Study: 27933698
Drug: Sofosbuvir 400
Normalized name: sofosbuvir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir 400 mg and weight-based ribavirin (1000 or 1200 mg) daily for 16 weeks
Study: 27933698
Drug: Sofosbuvir 400
Normalized name: sofosbuvir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir 400 mg and weight-based ribavirin (1000 or 1200 mg) daily for 24 weeks
Study: 27933698
Drug: Sofosbuvir plus
Normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sofosbuvir plus ribavirin therapy
Study: 25938158
Drug: Intravenous dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dexmedetomidine at a dose of 0.2 μg/kg.h for 12 hours
Study: 25938158
Drug: Intravenous normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous normal saline for 12 hours
Study: 23362991
Drug: Specific psychological
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific psychological intervention (6 sessions) along with fluoxetine
Study: 23362991
Drug: Non-specific psychological
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-specific psychological intervention (6 sessions) along with fluoxetine
Study: 18778179
Drug: Rosuvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (10 mg/day) for 16 weeks
Study: 16138713
Drug: Slow-release fluvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release fluvastatin 80 mg/day
Study: 16138713
Drug: Immediate-release fluvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release fluvastatin 40 mg/day
Study: 11876598
Drug: Topical corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroid (budesonide aqueous nasal spray: 128 microg b.i.d.)
Study: 7649341
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg dropropizine orally, three times daily for 3 days
Study: 7649341
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg levodropropizine orally, three times daily for 3 days
Study: 2668428
Drug: Ceftriaxone 2
Normalized name: ceftriaxone 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 2 g once a day
Study: 2668428
Drug: Cefotaxime 2
Normalized name: cefotaxime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime 2 g every 4 h
Study: 27886078
Drug: 500 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 µg vitamin B12 and 400 µg folic acid daily
Study: 22314083
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D supplement (1000 IU cholecalciferol/day)
Study: 12803583
Drug: Methylprednisolone (MP,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (MP, 15 mg kg‐1, n = 12)
Study: 12803583
Drug: Tirilazad mesylate
Normalized name: tirilazad mesylate
DrugBank: Tirilazad (DB13050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirilazad mesylate (TM, 10 mg kg‐1, n = 12)
Study: 10372428
Drug: Caffeine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (3 mg.kg‐1)
Study: 2102704
Drug: N-acetyl-L-cysteine
Normalized name: N-acetyl-L-cysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetyl-L-cysteine
Study: 1752851
Drug: Diphenhydramine 25‐50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine 25‐50 mg (N = 9)
Study: 30027612
Drug: Daily application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily application of the antiaging cream (0.1% RAL, GGO, Pre-tocopheryl) for 8 weeks
Study: 30027612
Drug: Three sequential
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three sequential glycolic acid (GA) peels (20%, 50%, and 70%) every 2-3 weeks
Study: 22471260
Drug: PLDLA implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLDLA implant arthroplasty
Study: 20595906
Drug: Ritonavir 200
Normalized name: lopinavir-ritonavir 200 mg-50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir 200 mg
Study: 17482177
Drug: Microdose GnRH
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microdose GnRH agonist flare (ML)
Study: 17482177
Drug: GnRH antagonist/letrozole
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH antagonist/letrozole (AL)
Study: 9524897
Drug: Acetylcholine (ACH)
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylcholine (ACH) infusion
Study: 28029445
Drug: E10030 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: E10030 1.5 mg in combination with ranibizumab 0.5 mg
Study: 28029445
Drug: E10030 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: E10030 0.3 mg in combination with ranibizumab 0.5 mg
Study: 28029445
Drug: Sham in
Normalized name: Amersham Indium (111In) Oxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham in combination with ranibizumab 0.5 mg (anti-VEGF monotherapy)
Study: 21843430
Drug: Free water
Normalized name: MENTHOL 2.5 mg ORAL LOZENGE [Halls Sugar Free Watermelon]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free water intake (treatment group)
Study: 16636167
Drug: Drugs for
Normalized name: DRUGS FOR CONSTIPATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs for atrial fibrillation
Study: 15658648
Drug: Shexiang Baoxin
Normalized name: CAMPHOR (NATURAL) 30.53 mg / MENTHOL 40.71 mg / METHYL SALICYLATE 25.95 mg TOPICAL PLASTER [SheXiang ZhuangGu Gao]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shexiang Baoxin pill (SBP)
Study: 9032192
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (800 mg twice daily for 2 weeks)
Study: 9032192
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (30 mg daily for 2 weeks)
Study: 2891867
Drug: Topical indometacin
Normalized name: indometacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical indometacin
Study: 2891867
Drug: Beta-blocker and
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker and pilocarpine 2%
Study: 26758700
Drug: α‐MSH levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: α‐MSH levels in obese children (1194±865 ng/mL)
Study: 26758700
Drug: AgRP levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: AgRP levels in obese children (828±417 ng/mL)
Study: 24313633
Drug: Sertraline 100
Normalized name: sertraline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 100 mg daily for 4 weeks (after initial 8 weeks of 50 mg)
Study: 24313633
Drug: Sertraline 50
Normalized name: sertraline 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 50 mg daily for 8 weeks, continued for 4 weeks
Study: 24313633
Drug: Sertraline 100
Normalized name: sertraline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 100 mg daily for 4 weeks
Study: 17234108
Drug: XP-828L 5
Normalized name: XP-102
DrugBank: XP-102 (DB18780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: XP-828L 5 g/d for 56 days
Study: 15469666
Drug: Quetiapine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (150 mg)
Study: 10648333
Drug: MST 20
Normalized name: MST 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: MST 20 mg 12 hourly
Study: 10648333
Drug: Morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulfate 10 mg IM 6 hourly
Study: 6149758
Drug: +cyanidanol-3 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: +cyanidanol-3 (2 g daily, 500 mg qds)
Study: 3780692
Drug: Spinal blockade
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal blockade with 0.5% bupivacaine (3 ml)
Study: 3780692
Drug: Epidural blockade
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural blockade with 0.5% bupivacaine (19 ml)
Study: 30045422
Drug: Oral Melissa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Melissa officinalis (MO) 3 g/d
Study: 20531162
Drug: Physical Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical Therapy (PT) intervention consisting of eight 90‐min sessions with 30 mins of each session devoted to PT, focusing on truncal and limb isodynamic strengthening and education.
Study: 20531162
Drug: Physical Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical Therapy (PT) intervention
Study: 17713476
Drug: Raltegravir (single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir (single-dose escalation study)
Study: 17713476
Drug: Raltegravir (multiple-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir (multiple-dose escalation study)
Study: 17713476
Drug: Raltegravir (single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir (single-dose female study)
Study: 17149454
Drug: Yoga intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yoga intervention (1 hour instructional session, followed by 4 weeks of daily home practice)
Study: 12511185
Drug: Insulin-sensitive (IS)
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-sensitive (IS) patients
Study: 12511185
Drug: Insulin-resistant (IR)
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-resistant (IR) patients
Study: 7859960
Drug: No prior
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prior intravenous sedation (second phase)
Study: 2680158
Drug: Aspirin (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (325 mg three times daily)
Study: 2680158
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and dipyridamole (325 mg and 75 mg, respectively, three times daily)
Study: 2680158
Drug: All aspirin
Normalized name: CAREALL Aspirin 81mg Chewable Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: All aspirin groups combined